On 20 January, partners of the AMYPAD project published a paper entitled “The Amyloid Imaging for the Prevention of Alzheimer’s Disease Consortium: A European collaboration with a global impact” in a Special Issue of the Frontiers in Neurology journal. The authors of the paper, including Alzheimer Europe Executive Director Jean Georges and Project Officer Cindy Birck, described the scientific landscape of Alzheimer’s disease, the objectives and main outcomes of the AMYPAD project. In this paper, authors highlighted the important collaborations necessary to make AMYPAD a successful consortium to reach not only the scientific community but also engage society at large, and illustrated how these endeavours ensured the value of the consortium during and after the funding period.
In summary, the AMYPAD consortium has made a strong contribution to the Alzheimer’s disease field. A legacy of over 3500 amyloid PET scans covering the entire Alzheimer’s disease continuum has been collected across the two AMYPAD clinical studies, which are now curated for sharing with the research community. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.